Advancement in Beneficial Effects of AVE 0991: A Brief Review

Abstract

AVE 0991, a non-peptide analogue of Angiotensin-(1-7) [Ang-(1-7)], is orally active and physiologically well tolerated. Several studies have demonstrated that AVE 0991 improves glucose and lipid metabolism, and contains anti-inflammatory, anti-apoptotic, anti-fibrosis, and anti-oxidant effects. Numerous preclinical studies have also reported that AVE 0991 appears to have beneficial effects on a variety of systemic diseases, including cardiovascular, liver, kidney, cancer, diabetes, and nervous system diseases. This study searched multiple literature databases, including PubMed, Web of Science, EMBASE, Google Scholar, Cochrane Library, and the ClinicalTrials.gov website from the establishment to October 2022, using AVE 0991 as a keyword. This literature search revealed that AVE 0991 could play different roles via various signaling pathways. However, the potential mechanisms of these effects need further elucidation. This review summarizes the benefits of AVE 0991 in several medical problems, including the COVID-19 pandemic. The paper also describes the underlying mechanisms of AVE 0991, giving in-depth insights and perspectives on the pharmaceutical value of AVE 0991 in drug discovery and development.

An emerging view on vascular fibrosis molecular mediators and relevant disorders: from bench to bed

“…Furthermore, diminazene aceturate (DIZE) as a ACE2 activator and AT1R inhibitor, shows alleviation to collagen accumulation in cardiac infraction mice ( 98 ). Besides ACE2 activators, researchers recently found a nonpeptide, Ang-1(1-7)-like compound named AVE 0991 that can selectively activates MasR and is of great potential as cardiovascular medicine ( 99 ). However, more evidences are needed when it comes to vascular fibrosis.…”